153 related articles for article (PubMed ID: 34702279)
1. Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models.
Li Q; Kim YS; An JH; Kwon JA; Han SH; Song WJ; Youn HY
BMC Vet Res; 2021 Oct; 17(1):338. PubMed ID: 34702279
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Activity of Rivoceranib Against Canine Mammary Gland Tumor Cell Lines.
Lee JH; Li Q; An JH; Chae HK; Choi JW; Kim BJ; Song WJ; Youn HY
Anticancer Res; 2019 Oct; 39(10):5483-5494. PubMed ID: 31570442
[TBL] [Abstract][Full Text] [Related]
3. Antitumour effects of Liporaxel (oral paclitaxel) for canine melanoma in a mouse xenograft model.
Yang JI; Jin B; Kim SY; Li Q; Nam A; Ryu MO; Lee WW; Son MH; Park HJ; Song WJ; Youn HY
Vet Comp Oncol; 2020 Jun; 18(2):152-160. PubMed ID: 31503379
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer effects of DHP107 on canine mammary gland cancer examined through in-vitro and in-vivo mouse xenograft models.
Chae HK; Oh YI; Lim GH; Jung YC; Park SH; An JH; Park SM; Seo KW; Chu SN; Li Q; Youn HY
BMC Vet Res; 2024 Jan; 20(1):3. PubMed ID: 38172758
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour effect of metformin in canine mammary gland tumour cells.
Saeki K; Watanabe M; Tsuboi M; Sugano S; Yoshitake R; Tanaka Y; Ong SM; Saito T; Matsumoto K; Fujita N; Nishimura R; Nakagawa T
Vet J; 2015 Aug; 205(2):297-304. PubMed ID: 25981932
[TBL] [Abstract][Full Text] [Related]
6. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
[TBL] [Abstract][Full Text] [Related]
7. Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Ong SM; Yamamoto H; Saeki K; Tanaka Y; Yoshitake R; Nishimura R; Nakagawa T
Jpn J Vet Res; 2017 Feb; 65(1):17-28. PubMed ID: 29791117
[TBL] [Abstract][Full Text] [Related]
8. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling.
Diao H; Cheng N; Zhao Y; Xu H; Dong H; Thamm DH; Zhang D; Lin D
BMC Vet Res; 2019 Aug; 15(1):276. PubMed ID: 31375107
[TBL] [Abstract][Full Text] [Related]
9. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Effects of Mitoquinone via Cell Cycle Arrest and Apoptosis in Canine Mammary Gland Tumor Cells.
Lee R; Lee WY; Park HJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732133
[TBL] [Abstract][Full Text] [Related]
11. A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma.
Orecchia P; Conte R; Balza E; Petretto A; Mauri P; Mingari MC; Carnemolla B
Eur J Cancer; 2013 May; 49(8):2022-33. PubMed ID: 23352437
[TBL] [Abstract][Full Text] [Related]
12. Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.
Jang S; Strickland B; Finis L; Kooijman JJ; Melis JJTM; Zaman GJR; Van Tornout J
Cancer Chemother Pharmacol; 2023 Jun; 91(6):491-499. PubMed ID: 37148323
[TBL] [Abstract][Full Text] [Related]
13. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.
Mellinas-Gomez M; Spanswick VJ; Paredes-Moscosso SR; Robson M; Pedley RB; Thurston DE; Baines SJ; Stell A; Hartley JA
BMC Vet Res; 2015 Aug; 11():215. PubMed ID: 26282406
[TBL] [Abstract][Full Text] [Related]
14. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour.
Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T
Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327
[TBL] [Abstract][Full Text] [Related]
15. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2.
Lai L; Liu J; Zhai D; Lin Q; He L; Dong Y; Zhang J; Lu B; Chen Y; Yi Z; Liu M
Br J Pharmacol; 2012 Feb; 165(4b):1084-96. PubMed ID: 21658027
[TBL] [Abstract][Full Text] [Related]
16. Effects of NF-κB expression and its inhibition on canine mammary cancer cell lines in an immunodeficient mice model.
Mkaouar L; Endo Y; Mochizuki M; Nishimura R; Sasaki N; Nakagawa T
J Vet Med Sci; 2011 Dec; 73(12):1539-46. PubMed ID: 21768753
[TBL] [Abstract][Full Text] [Related]
17. Spica prunellae promotes cancer cell apoptosis, inhibits cell proliferation and tumor angiogenesis in a mouse model of colorectal cancer via suppression of stat3 pathway.
Lin W; Zheng L; Zhuang Q; Zhao J; Cao Z; Zeng J; Lin S; Xu W; Peng J
BMC Complement Altern Med; 2013 Jun; 13():144. PubMed ID: 23800091
[TBL] [Abstract][Full Text] [Related]
18. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.
Qiu H; Li J; Liu Q; Tang M; Wang Y
Cell Cycle; 2018; 17(10):1235-1244. PubMed ID: 29886786
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines.
Seo KW; Coh YR; Rebhun RB; Ahn JO; Han SM; Lee HW; Youn HY
Res Vet Sci; 2014 Jun; 96(3):482-6. PubMed ID: 24656746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
